Importantly, T-EV has demonstrated significant apoptotic effects in TRAIL-resistant cancer cells, suggesting that EV-TRAIL could serve as a viable alternative to rTRAIL for cancer treatment, yielding superior therapeutic outcomes 380. The gene discussed is TNFSF10; the disease is cancer.